2021/02/25 by Francois Gonzalvez, Sylvie Vincent, Theresa E. Baker +23 · 4 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Treatments and Mutations #PI3K/AKT/mTOR signaling in cancer #Cancer Mechanisms and Therapy #Exon #Mutant #Cancer research #Mutation #Lung cancer #Cancer #Biology #Medicine #Genetics #Pathology #Gene
paper · pdf · doi:10.1158/2159-8290.cd-20-1683
openalex publication_date 2021/02/25 · openalex created_date 2021/03/01 · openalex updated_date 2026/07/09
Abstract Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non–small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting EGFR-mutated NSCLC, mobocertinib (TAK-788), a novel irreversible EGFR TKI, was specifically designed to potently inhibit oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. The in vitro and in vivo activity of mobocertinib was evaluated in engineered and patient-derived models harboring diverse EGFRex20ins mutations. Mobocertinib inhibited viability of various EGFRex20ins-driven cell lines more potently than approved EGFR TKIs and demonstrated in vivo antitumor efficacy in patient-derived xenografts and murine orthotopic models. These findings support the ongoing clinical development of mobocertinib for the treatment of EGFRex20ins-mutated NSCLC. Significance: No oral EGFR-targeted therapies are approved for EGFR exon 20 insertion (EGFRex20ins) mutation-driven NSCLC. Mobocertinib is a novel small-molecule EGFR inhibitor specifically designed to target EGFRex20ins mutants. Preclinical data reported here support the clinical development of mobocertinib in patients with NSCLC with EGFR exon 20 insertion mutations. See related commentary by Pacheco, p. 1617. This article is highlighted in the In This Issue feature, p. 1601